Eli Lilly (LLY) news

Older LLY news events, each with the realized, point-in-time move the market made — page 7 of 8. Back to the LLY overview → · Full LLY reaction history →

Latest news

Recent LLY events, each with its measured reaction. (Page 7 of 8.)

DateHeadlineEventSource5-minTo close
Form 8-K ELI LILLY & Co For: Aug 12SEC filing · Form 8-KSEC EDGAR+0.11%+0.65%
Lilly opens state-of-the-art research and development center in the Boston SeaportPress releasePR Newswire+0.08%+1.46%
Form 10-Q ELI LILLY & Co For: Jun 30SEC filing · Form 10-QSEC EDGAR+0.17%+1.59%
Form 8-K ELI LILLY & Co For: Aug 08SEC filing · Form 8-KSEC EDGAR-2.75%-3.17%
Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 BillionPress releasePR Newswire-2.75%-3.17%
Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesityPress releasePR Newswire-0.87%-0.04%
Lilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results AnnouncementPress releasePR Newswire-0.65%-1.07%
Form 8-K ELI LILLY & Co For: Jul 05SEC filing · Form 8-KSEC EDGAR-0.07%+0.34%
GordonMD® Global Investments Portfolio Company, Radionetics Oncology, Announced Strategic Agreement with LillyPress releaseBusiness Wire-0.30%+0.25%
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel DiseasePress releasePR Newswire-0.30%+0.25%
Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's DiseasePress releasePR Newswire+0.33%+0.61%
Health Canada Authorizes Lilly's Ebglyss™ (lebrikizumab) for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults and Adolescents 12 Years and OlderPress releaseCanada Newswire-0.14%+0.99%
Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteriaPress releasePR Newswire+0.20%+1.08%
Form 11-K ELI LILLY & Co For: Dec 31SEC filing · Form 11-KSEC EDGAR-0.14%+0.99%
Lilly Declares Third-Quarter 2024 DividendPress releasePR Newswire-0.07%-0.79%
LILLY'S TIRZEPATIDE REDUCED OBSTRUCTIVE SLEEP APNEA (OSA) SEVERITY, WITH UP TO 51.5% OF PARTICIPANTS MEETING THE CRITERIA FOR DISEASE RESOLUTIONPress releaseCanada Newswire-0.07%-0.79%
Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolutionPress releasePR Newswire+0.29%+0.16%
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs RisesPress releaseGlobeNewswire-2.08%-1.61%
Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeksPress releasePR Newswire-0.34%+1.29%
Form 8-K ELI LILLY & Co For: Jun 02SEC filing · Form 8-KSEC EDGAR-0.34%+0.21%
Lilly announces departure of Anat Ashkenazi, chief financial officerPress releasePR Newswire-0.34%+0.21%
Melissa Seymour to join Lilly as executive vice president of Global QualityPress releasePR Newswire-0.89%-0.21%
Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual MeetingPress releasePR Newswire+0.55%+1.44%
Lilly, UNICEF expand support to help millions of young people at risk of noncommunicable diseasesPress releasePR Newswire+0.34%+0.78%
Lilly to Participate in Goldman Sachs 45th Annual Global Healthcare ConferencePress releasePR Newswire+0.13%+2.14%
Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline MedicinesPress releasePR Newswire+0.01%-0.07%
Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual MeetingPress releasePR Newswire+0.01%-0.07%
More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved clinical remission at one year, including patients with previous biologic failurePress releasePR Newswire+1.91%+1.15%
With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily InsulinPress releasePR Newswire-0.09%-1.84%
Alonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance OfficerPress releasePR Newswire+0.12%+2.99%
Form 8-K ELI LILLY & Co For: May 06SEC filing · Form 8-KSEC EDGAR-0.01%-1.92%
Lilly Declares Second-Quarter 2024 DividendPress releasePR Newswire-0.09%+2.13%
Form SD ELI LILLY & CoSEC filing · Form SDSEC EDGAR+0.52%+3.88%
Form 10-Q ELI LILLY & Co For: Mar 31SEC filing · Form 10-QSEC EDGAR-0.28%+0.91%
Form 8-K ELI LILLY & Co For: Apr 30SEC filing · Form 8-KSEC EDGAR+1.24%+1.05%
Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline MomentumPress releasePR Newswire+1.24%+1.05%
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesityPress releasePR Newswire-0.13%-1.21%
Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results AnnouncementPress releasePR Newswire+0.04%-0.40%
Form DEF 14A ELI LILLY & Co For: Mar 22SEC filing · Form DEFSEC EDGAR-0.18%+0.28%
Form DEFA14A ELI LILLY & CoSEC filing · Form DEFA14ASEC EDGAR-0.18%+0.28%
More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab studyPress releasePR Newswire-1.73%-2.55%
Form PRE 14A ELI LILLY & Co For: Mar 08SEC filing · Form PRESEC EDGAR-1.73%-2.55%
U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of DonanemabPress releasePR Newswire-0.89%-1.79%
Lilly's Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity CarePress releasePR Newswire+0.27%+0.94%
Lilly Announces Details of Presentations at 2024 American Association for Cancer Research (AACR) Annual MeetingPress releasePR Newswire-0.05%-0.45%
Form 10-K ELI LILLY & Co For: Dec 31SEC filing · Form 10-KSEC EDGAR+0.07%+0.37%
Lilly to Participate in Cowen's 44th Annual Health Care ConferencePress releasePR Newswire+0.09%-1.86%
Form 8-K ELI LILLY & Co For: Feb 07SEC filing · Form 8-KSEC EDGAR-0.14%+0.09%
Philip Johnson to Retire as Lilly TreasurerPress releasePR Newswire+0.52%+0.70%
Form 8-K ELI LILLY & Co For: Feb 06SEC filing · Form 8-KSEC EDGAR-1.69%-4.47%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Stop guessing what the event means.

claude mcp add news-quantified
Get free API keyTry the playground